Stephen C Goff

Address:

7801 Constitution Dr, Plano, TX 75025

VIN:

KNDJT2A29B7736520

Make:

KIA

Model:

SOUL

Year:

2011

US Patent:

6372502, Apr 16, 2002

Filed:

Nov 17, 1994

Appl. No.:

08/341269

Inventors:

Arthur Bank - Riverdale NY
Dina G. Markowitz - New York NY
Stephen P. Goff - Tenafly NJ

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C12N 1587

US Classification:

435465, 435455, 435325, 435354, 435357

Abstract:

This invention provides a mammalian cell useful for retroviral packaging comprising two plasmids, both of which comprise the 5â long terminal repeat (LTR) sequence from a helper virus, neither of which comprise a functional packaging sequence or a 3â LTR from the helper virus, one of which comprises the env gene from the helper virus and the other of which comprises the gag and pol genes from the helper virus. This invention also provides a process for preparing a producer cell useful for transferring a foreign gene into a mammalian cell which comprises treating the above-described mammalian cell with a vector plasmid so as to insert the vector plasmid into the cell and thus create the producer cell, the vector plasmid comprising the foreign gene, a functional packaging sequence from the helper virus, both the 5â and 3â LTRS from the helper virus, and a gene encoding a selectable or identifiable phenotypic trait, and recovering the producer cell so created.

US Patent:

6469153, Oct 22, 2002

Filed:

May 20, 1998

Appl. No.:

09/082358

Inventors:

Stephen P. Goff - Tenafly NJ
Xingqiang Li - Chestnut Hill MA

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C07H 2104

US Classification:

536 235, 4353201, 435 691

Abstract:

This invention provides isolated nucleic acid molecules encoding envelope-interacting protein-1 and envelope-interacting protein-3. This invention provides fusion proteins comprising EIP-1, EIP-3, or fragments thereof and a second peptide. This invention provides vectors comprising the isolated nucleic acid molecule, encoding mammalian EIP-1 and EIP-3. This invention provides plasmid designated pCGN-EIP-l and pCGN-EIP-3. This invention provides purified mammalian EIP-1 and EIP-3 proteins. This invention provides monoclonal or polyclonal antibodies directed to epitopes of an EIP-1 or an EIP-3. This invention provides a method of increasing transduction efficieny of a retrovirus on target cells comprising: a) incubating an envelope-interacting protein with a retrovirus; and b) transducing the target cells with the retrovirus. This invention provide methods of treating patient with a therapeutic gene comprising use of transducing viruses incubated with an effective amount of an envelope-interacting protein effective to enhance retroviral infectivity. This invention also provides pharmaceutical composition comprising an envelope-interacting protein bound retroviral virion comprising a therapeutic gene and a pharmaceutically acceptable carrier capable of passing through a cell membrane.

US Patent:

6812025, Nov 2, 2004

Filed:

Jun 12, 2002

Appl. No.:

10/009433

Inventors:

Stephen P. Goff - Tenafly NJ
Gilda Tachedjian - New York NY

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C12N 516

US Classification:

4353391, 435 5, 435 6, 435 697

Abstract:

This invention provides methods of determining whether a compound inhibits HIV-1 reverse transcriptase. This invention provides methods of determining whether a compound inhibits formation of a complex between a p66 and p51 subunit polypeptides of HIV-1 reverse transcriptase. This invention provides a method of determining whether a compound enhances formation of a complex between a p66 and p51 subunit polypeptides of HIV-1 reverse transcriptase. This invention provides methods of determining whether a compound inhibits formation of a complex between two p66 subunit polypeptides of HIV-1 reverse transcriptase. This invention provides methods of determining whether a compound enhances formation of a complex between two p66 subunit polypeptides of HIV-1 reverse transcriptase.

US Patent:

20030007983, Jan 9, 2003

Filed:

Dec 6, 2001

Appl. No.:

10/006626

Inventors:

Stephen Goff - Tenafly NJ, US
Gilda Tachedjian - East Malvern, AU
Bryan O'Hara - Norwood NJ, US

International Classification:

C12Q001/70
C12P021/06
C12P019/34
A61K039/00
A61K039/38
A61K039/21

US Classification:

424/208100, 424/207100, 424/184100, 435/005000, 435/091100, 435/069100

Abstract:

This invention provides methods of determining whether a compound inhibits HIV-1 reverse transcriptase. This invention provides methods of determining whether a compound inhibits formation of a complex between a p66 and p51 subunit polypeptides of HIV-1 reverse transcriptase. This invention provides a method of determining whether a compound enhances formation of a complex between a p66 and p51 subunit polypeptides of HIV-1 reverse transcriptase. This invention provides methods of determining whether a compound inhibits formation of a complex between two p66 subunit polypeptides of HIV-1 reverse transcriptase. This invention provides methods of determining whether a compound enhances formation of a complex between two p66 subunit polypeptides of HIV-1 reverse transcriptase.

US Patent:

20070025967, Feb 1, 2007

Filed:

Aug 12, 2004

Appl. No.:

10/568396

Inventors:

Stephen Goff - Tenafly NJ, US
Guanxia Gao - Beijing, CN

International Classification:

A61K 48/00
A61K 38/48
C12Q 1/70
C12Q 1/68
C07H 21/04
C12P 21/06
C12N 9/12

US Classification:

424093200, 435006000, 435069100, 435194000, 435320100, 435325000, 424094500, 536023200, 435005000

Abstract:

This invention provides an isolated ZAP protein and methods and articles of manufacture for increasing resistance to a virus in a subject or mammalian cell. The instant methods and articles are based on the use the ZAP protein to increase such resistance to a virus.

US Patent:

52780562, Jan 11, 1994

Filed:

Apr 29, 1992

Appl. No.:

7/877269

Inventors:

Arthur Bank - Riverdale NY
Dina G. Markowitz - New York NY
Stephen P. Goff - Tenafly NJ

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C12N 506
C12N 1586

US Classification:

4351723

Abstract:

The invention relates to a mammalian cell line useful for retroviral packaging comprising two plasmids, the first such plasmid comprising in 5' to 3' order: a DNA sequence comprising a 5' long terminal repeat (LTR); a mutated. psi. packaging sequence; a DNA sequence comprising the encoding portion of the Moloney murine leukemia virus (MULV) env gene; and the second such plasmid comprising in 5' to 3' order: a DNA sequence comprising a 5' long terminal repeat (LTR); a mutated. psi. packaging sequence; a DNA sequence comprising the encoding portion of the Moloney murine leukemia virus (MULV) gag and pol genes; a selectable marker; and an origin of replication. The invention also relates to processes for preparing a producer cell line useful for transferring a gene of interest into recipient mammalian cells in vitro.

US Patent:

52565548, Oct 26, 1993

Filed:

Dec 2, 1991

Appl. No.:

7/800682

Inventors:

Stephen P. Goff - Tenafly NJ
Naoko Tanese - New York NY
William A. Haseltine - Cambridge MA

Assignee:

The Trustees of Columbia University in the City of New York - New York NY
The Dana Farber Cancer Institute - Boston MA

International Classification:

C12N 900
C12N 1549

US Classification:

435183

Abstract:

This invention describes pHRT25, a plasmid containing a modified pol gene of the Human Immunodeficiency Virus Type 1 (HIV-1), formerly HTLV-III, under control of an inducible trp promoter. Methods of expressing reverse transcriptase activity using pHRT25 in E. coli are described.

US Patent:

52022595, Apr 13, 1993

Filed:

Dec 28, 1988

Appl. No.:

7/291125

Inventors:

Stephen P. Goff - Tenafly NJ
Naoko Tanese - Berkeley CA

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C12N 121
C12N 912
C12N 1510

US Classification:

43525233

Abstract:

This invention provides a plasmid identified as pHRTRX2 and deposited in E. coli HB101 under ATCC Accession No. 67828. The invention also provides for a polypeptide having HIV reverse transcriptase activity and for a method by which the polypeptide can be prepared which comprises growing a host cell comprising the plasmid pHRTRX2 under suitable conditions permitting production of the polypeptide and recovering the resulting polypeptide.